Rutgers New Jersey Medical School will be a clinical test site for a study assessing the long term risk of chronic kidney disease in patients who recover from COVID-19. The Multi-Center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID) study – conducted by the Division of Nephrology at Mount Sinai – will assess risk in up to 4,000 patients who have recovered from COVID-19 using the artificial-intelligence diagnostic system KidneyIntelX that can incorporate novel protein biomarkers and provide insight into the disease. Researchers will also study patients’ COVID-19 antibody levels over time, which will provide insights into the interaction between immune response and kidney-related complications. Initial research findings are expected to be reported in early 2021. To read the full story.
Recent Posts
- New Charts for Artery Stiffness Could Flag Heart Risk Long Before Symptoms.
- When It Comes to Breastfeeding, Study Shows Timing Is an Important Consideration.
- A Rutgers Scientist Confronts the Assertive “Bouncer” of the Brain, Seeking Insights into Human Health.
- Nicotine Pouches May Offer Path to Reduced Tobacco Harm.
- Soot’s Climate-Altering Properties Change Within Hours of Entering Atmosphere.
Categories
- Community (2,340)
- Covid (991)
- CTO Events (6)
- News (2,975)
- Pilots (21)